Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (51-60 of 375) with videos related to

Pageof 38
Sort By:
Therapeutic Advances in Medical Oncology|June 19, 2025
Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyondKazumasa Yamamoto, Izuma Nakayama, Kohei Shitara
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 20, 2007
Suspected paclitaxel-induced pneumonitisKohei Shitara, Eiji Ishii, Makoto Kondo, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 11, 2006
[S-1 for gastric cancer-S-1 monotherapy and its progress]Kohei Shitara, Yuh Sakata, Toshihiro Kudou, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 14, 2007
A case of suspected S-1 induced interstitial pneumoniaKohei Shitara, Masaki Munakata, Wasaburo Koizumi, et al.
Journal of Gastric Cancer|January 10, 2026
CLDN18.2 in Gastric Cancer: Current Therapeutic Landscape and Future PerspectivesFei Zhang, Ukyo Okazaki, Izuma Nakayama, et al.
Expert Review of Anticancer Therapy|February 5, 2026
An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)Kyosuke Seguchi, Akihito Kawazoe, Izuma Nakayama, et al.
Cancer Management and Research|October 24, 2022
Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese ExperienceYohei Kubota, Yu Aoki, Akihito Kawazoe, et al.
Japanese Journal of Clinical Oncology|June 24, 2008
Metastatic rectal cancer responding to third-line therapy employing bevacizumab after failure of oxaliplatin and irinotecan: case reportKohei Shitara, Masaki Munakata, Osamu Muto, et al.
Current Problems in Cancer|October 25, 2024
Current landscape of targeted therapy in esophageal squamous cell carcinomaAmane Jubashi, Daisuke Kotani, Takashi Kojima, et al.
International Journal of Clinical Oncology|October 24, 2006
Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapyKohei Shitara, Atushi Ishiguro, Masaki Munakata, et al.
Pageof 38

Showing results (51-60 of 375) with videos related to

Sort By:
Pageof 38
Therapeutic Advances in Medical Oncology|June 19, 2025
Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyondKazumasa Yamamoto, Izuma Nakayama, Kohei Shitara
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 20, 2007
Suspected paclitaxel-induced pneumonitisKohei Shitara, Eiji Ishii, Makoto Kondo, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 11, 2006
[S-1 for gastric cancer-S-1 monotherapy and its progress]Kohei Shitara, Yuh Sakata, Toshihiro Kudou, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 14, 2007
A case of suspected S-1 induced interstitial pneumoniaKohei Shitara, Masaki Munakata, Wasaburo Koizumi, et al.
Journal of Gastric Cancer|January 10, 2026
CLDN18.2 in Gastric Cancer: Current Therapeutic Landscape and Future PerspectivesFei Zhang, Ukyo Okazaki, Izuma Nakayama, et al.
Expert Review of Anticancer Therapy|February 5, 2026
An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)Kyosuke Seguchi, Akihito Kawazoe, Izuma Nakayama, et al.
Cancer Management and Research|October 24, 2022
Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese ExperienceYohei Kubota, Yu Aoki, Akihito Kawazoe, et al.
Japanese Journal of Clinical Oncology|June 24, 2008
Metastatic rectal cancer responding to third-line therapy employing bevacizumab after failure of oxaliplatin and irinotecan: case reportKohei Shitara, Masaki Munakata, Osamu Muto, et al.
Current Problems in Cancer|October 25, 2024
Current landscape of targeted therapy in esophageal squamous cell carcinomaAmane Jubashi, Daisuke Kotani, Takashi Kojima, et al.
International Journal of Clinical Oncology|October 24, 2006
Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapyKohei Shitara, Atushi Ishiguro, Masaki Munakata, et al.
Pageof 38